• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Eton Pharmaceuticals Inc.

    11/19/25 5:19:25 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ETON alert in real time by email
    S-8 1 eton20251001_s8.htm FORM S-8 eton20251001_s8.htm

    Registration No. 333-



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     


    FORM S-8

    REGISTRATION STATEMENT

    Under

    THE SECURITIES ACT OF 1933

     


     

    Eton Pharmaceuticals, Inc.

    (Exact name of registrant as specified in its charter)

     


     

    Delaware

    (State or other jurisdiction of

    incorporation or organization)

    37-1858472

    (I.R.S. Employer

    Identification No.)

     

     

     

     

     

    21925 W. Field Parkway, Suite 235

    Deer Park, Illinois 60010

    (Address of Principal Executive Offices) (Zip Code)

     

    2018 Equity Incentive Plan

    2018 Employee Stock Purchase Plan

    (Full titles of the plans)

     

    Sean E. Brynjelsen

    President and Chief Executive Officer

    Eton Pharmaceuticals, Inc.

    21925 W. Field Parkway, Suite 235

    Deer Park, Illinois 60010

    (847) 787-7361

     

     

    (Name, address, and telephone number, including area code, of agent for service)

     


     

    Copies to:

     

    Geoffrey R. Morgan, Esq.

    Croke Fairchild Duarte & Beres LLC

    180 N. LaSalle St., Suite 3400

    Chicago, Illinois 60601

    Tel: (312) 768-4700

    Sean E. Brynjelsen

    President and Chief Executive Officer

    Eton Pharmaceuticals, Inc.

    21925 W. Field Parkway, Suite 235

    Deer Park, Illinois 60010

    (847) 787-7361

     


     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non- accelerated filer

    ☒

    Smaller reporting company

    ☒

       

    Emerging growth company

    ☐

     

     

    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     



     

     

     

     

     

    EXPLANATORY NOTE

     

    Eton Pharmaceuticals, Inc. (the “Registrant”) has prepared this registration statement (this “Registration Statement”) in accordance with the requirements of Form S-8 under the Securities Act to register 1,068,363 additional shares of Common Stock reserved for issuance under the Eton Pharmaceuticals, Inc. 2018 Equity Incentive Plan (the “2018 Plan”) and 150,000 additional shares of Common Stock reserved for issuance under the Eton Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan (the “2018 ESPP”).

     

    Pursuant to the Registration Statements on Form S-8 (File Nos. 333-228493, 333-230572, 333-270707 and 333-278234) filed by the Registrant with the Securities and Exchange Commission (the “Commission”) on November 20, 2018, March 28, 2019, March 21, 2023 and March 25, 2024 (the “Prior Registration Statements”), the Registrant previously registered an aggregate of 7,699,634 shares of Common Stock under the 2018 Plan and an aggregate of 1,050,000 shares of Common Stock under the 2018 ESPP.

     

    In accordance with General Instruction E to Form S-8, the contents of the Prior Registration Statements are hereby incorporated by reference.

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS

     

    The information specified in Item 1 and Item 2 of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”) and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

     

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.

     

     

    The following documents filed by the Registrant with the Commission are hereby incorporated by reference into this Registration Statement:

     

    (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 18, 2025;
    (b) The Registrant’s Current Reports on Form 8-K filed with the Commission on January 3, 2025, February 6, 2025, February 7, 2025, March 3, 2025, March 7, 2025, March 14, 2025, March 18, 2025, April 1, 2025, April 28, 2025, May 2, 2025, May 28, 2025, June 10, 2025, June 20, 2025, June 27, 2025, July 8, 2025 (other than with respect to Item 2.02 and Exhibit 99.1 thereof); March 18, 2025, May 13, 2025, August 7, 2025, November 6, 2025 and November 18, 2025; and the Registrant's Quarterly Reports on Form 10-Q filed with the Commission on May 13, 2025, August 7, 2025, and November 6, 2025 and
    (c) The description of the Common Stock set forth in the Registrant’s Registration Statement on Form 8-A12B (File No. 001-38738), filed with the Commission on November 8, 2018, including any amendments or reports filed for the purpose of updating such description.

     

    All other reports and other documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be part of this Registration Statement from the date of the filing of such reports and documents, except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under Items 2.02 or 7.01 of Form 8-K that is not deemed filed under such provisions.

     

    For purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    You should rely only on the information provided or incorporated by reference in this Registration Statement or any related prospectus. The Registrant has not authorized anyone to provide you with different information. You should not assume that the information in this Registration Statement or any related prospectus is accurate as of any date other than the date on the front of the document.

     

    You may contact the Registrant in writing or orally to request copies of the above-referenced filings, without charge (excluding exhibits to such documents unless such exhibits are specifically incorporated by reference into the information incorporated into this Registration Statement). Requests for such information should be directed to:

     

     

    Eton Pharmaceuticals, Inc.

    21925 W. Field Parkway, Suite 235

    Deer Park, Illinois 60010

    (847) 787-7361

    Attn: Chief Executive Officer

     

     

     

     

     

    Item 8. EXHIBITS.

     

     

     

    Exhibit

     

    Number

    Description

       

    4.1

    Amended and Restated Certificate of Incorporation of the Registrant ( incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38738), filed with the Commission on November 20, 2018).

       

    4.2

    Amended and Restated Bylaws of the Registrant ( incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-38738), filed with the Commission on November 20, 2018).

       

    4.3

    Specimen Certificate representing shares of common stock of Registrant (incorporated by reference to Exhibit 4.1 on the Registrant’s Registration Statement on Form S -1 ( File No. 333-226774), as amended, originally filed with the Commission on August 10, 2018).

       

    5.1*

    Opinion of Croke Fairchild Duarte & Beres LLC.

       

    23.1*

    Consent of Crowe LLP, Independent Registered Public Accounting Firm.

       
    23.2* Consent of KMJ Corbin & Company LLP, Independent Registered Public Accounting Firm.
       

    23.3*

    Consent of Croke Fairchild Duarte & Beres LLC (contained in Exhibit 5.1).

       

    24.1*

    Power of Attorney (contained on signature pages hereto).

       

    99.1

    Eton Pharmaceuticals, Inc. 2018 Equity Incentive Plan as amended December 2020 and Forms of Stock Option Agreement, Notice of Exercise and Stock Option Grant Notice thereunder (incorporated by reference to Exhibit 10.11 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 and filed on March 16, 2021)

       

    99.2

    Eton Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.17 to the Registrant’s Registration Statement on Form S-1 (File No. 333-226774), as amended, originally filed with the Commission on August 10, 2018).

       

    107*

    Filing Fee Table

     

     

     

    *Filed herewith

     

     

     

     

     

    SIGNATURES

     

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Deer Park, State of Illinois, on November 19, 2025.

     

    Eton Pharmaceuticals, Inc.

     

     

    By:

    /s/ Sean E. Brynjelsen

     
     

    Sean E. Brynjelsen

     
     

    President and Chief Executive Officer

     

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Sean E. Brynjelsen and James R. Gruber, and each or any one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

     

    Signature

     

    Title

     

    Date

             
       

    President, Chief Executive Officer and Director

       

    /s/ Sean E. Brynjelsen

     

    (Principal Executive Officer)

     

    November 19, 2025

    Sean E. Brynjelsen

           
             
       

    Chief Financial Officer

       

    /s/ James R. Gruber

     

    (Principal Financial and Accounting Officer)

     

    November 19, 2025

    James R. Gruber

           
             

    /s/ Jennifer M. Adams

     

    Director

     

    November 19, 2025

    Jennifer M. Adams

           
             

    /s/ Charles J. Casamento

     

    Director

     

    November 19, 2025

    Charles J. Casamento

           
             

    /s/ Paul V. Maier

     

    Director

     

    November 19, 2025

    Paul V. Maier

           
             

    /s/ Norbert G. Riedel

     

    Director

     

    November 19, 2025

    Norbert G. Riedel, Ph.D.

           

     

     

     

     

     

     
    Get the next $ETON alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ETON

    DatePrice TargetRatingAnalyst
    1/23/2025$17.00 → $33.00Buy
    H.C. Wainwright
    1/10/2025$21.00Buy
    B. Riley Securities
    1/6/2025$15.00 → $17.00Buy
    H.C. Wainwright
    9/4/2024$9.00Buy
    H.C. Wainwright
    5/6/2024$8.00Buy
    Craig Hallum
    10/14/2021$10.00Buy
    B. Riley Securities
    More analyst ratings

    $ETON
    SEC Filings

    View All

    SEC Form S-8 filed by Eton Pharmaceuticals Inc.

    S-8 - Eton Pharmaceuticals, Inc. (0001710340) (Filer)

    11/19/25 5:19:25 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Eton Pharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Other Events

    8-K/A - Eton Pharmaceuticals, Inc. (0001710340) (Filer)

    11/18/25 4:16:47 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Eton Pharmaceuticals Inc.

    10-Q - Eton Pharmaceuticals, Inc. (0001710340) (Filer)

    11/6/25 4:28:53 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Opaleye Management Inc. bought $125,484 worth of shares (7,930 units at $15.82) (SEC Form 4)

    4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

    6/12/25 4:32:51 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Opaleye Management Inc. bought $79,814 worth of shares (10,000 units at $7.98) (SEC Form 4)

    4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

    10/25/24 4:05:24 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Opaleye Management Inc. bought $434,137 worth of shares (62,070 units at $6.99) (SEC Form 4)

    4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

    10/8/24 6:34:32 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright reiterated coverage on Eton Pharmaceuticals with a new price target

    H.C. Wainwright reiterated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $33.00 from $17.00 previously

    1/23/25 9:02:14 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Eton Pharmaceuticals with a new price target

    B. Riley Securities initiated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $21.00

    1/10/25 7:49:32 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright reiterated coverage on Eton Pharmaceuticals with a new price target

    H.C. Wainwright reiterated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $17.00 from $15.00 previously

    1/6/25 8:01:16 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Gruber James R. sold $673,714 worth of shares (41,713 units at $16.15), decreasing direct ownership by 16% to 204,753 units (SEC Form 4)

    4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

    8/20/25 5:14:03 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Business Officer Krempa David sold $504,318 worth of shares (34,000 units at $14.83), decreasing direct ownership by 5% to 612,646 units (SEC Form 4)

    4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

    6/16/25 4:56:08 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Opaleye Management Inc. bought $125,484 worth of shares (7,930 units at $15.82) (SEC Form 4)

    4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

    6/12/25 4:32:51 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th

    DEER PARK, Ill., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host 1x1 meetings at the 16th Annual Craig-Hallum Alpha Select Conference being held November 18, 2025 in New York, NY. To schedule a 1x1 meeting with the Company, please contact your Craig-Hallum institutional sales representative. About Eton PharmaceuticalsEton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company curr

    11/12/25 4:30:00 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results

    Q3 2025 product sales of $22.5 million, representing 129% growth over Q3 2024 and 19th straight quarter of sequential product sales growthQ3 2025 basic and fully diluted GAAP EPS of $(0.07), non-GAAP fully diluted EPS of $0.04, and Adjusted EBITDA of $2.9 millionET-600 NDA accepted for review, assigned PDUFA date of February 25, 2026GALZIN® launch ahead of plan; exceeded previous year-end target of 200 active patientsHeld positive FDA meeting clarifying pathway to KHINDIVI™ label expansionSubmitted proposed clinical study to support INCRELEX® label expansionGenerated $12.0 million of cash from operations in the quarterManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., No

    11/6/25 4:05:00 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

    DEER PARK, Ill., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Participant Call Link:Click HereWebcast:Click Here   In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@eto

    10/23/25 4:30:00 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETON
    Leadership Updates

    Live Leadership Updates

    View All

    Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

    Ms. Erdogan-Trinkaus brings a wealth of commercial leadership and expertise in sales and marketing from her tenure at leading global pharmaceutical companies and across the broader health and wellness sector, including significant experience in the pediatric endocrinology specialty. DEER PARK, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Ipek Erdogan-Trinkaus as Chief Commercial Officer (CCO). Ms. Erdogan-Trinkaus brings to the Company broad commercial experience in the pharmaceutical

    12/3/24 6:50:00 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer

    DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of James Gruber as Chief Financial Officer, effective immediately. He succeeds Wilson Troutman, who is retiring. Mr. Troutman will remain with the company through the end of May to ensure a smooth transition. "We are pleased to welcome James to the Eton team. He brings a wealth of experience managing the finance and accounting activities for some of the most successful companies in the industry. We look forward to benefiting from his financial expertise as we

    4/11/22 4:01:00 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director

    LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that Mr. Paul Maier has been appointed as a non-executive independent director of the board of directors of the Company (the "Board"). He will hold office as an independent director until the next annual meeting of shareholders, or until his successor has been elected or appointed. Mr. Maier has also been appointed as a member of the Audit Committee and Corporate Governance and Nominating Committee and Chair of the Compensation Committee. Mr. Maier joins Small Pharma with over 30 years' ex

    11/18/21 2:04:01 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETON
    Financials

    Live finance-specific insights

    View All

    Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results

    Q3 2025 product sales of $22.5 million, representing 129% growth over Q3 2024 and 19th straight quarter of sequential product sales growthQ3 2025 basic and fully diluted GAAP EPS of $(0.07), non-GAAP fully diluted EPS of $0.04, and Adjusted EBITDA of $2.9 millionET-600 NDA accepted for review, assigned PDUFA date of February 25, 2026GALZIN® launch ahead of plan; exceeded previous year-end target of 200 active patientsHeld positive FDA meeting clarifying pathway to KHINDIVI™ label expansionSubmitted proposed clinical study to support INCRELEX® label expansionGenerated $12.0 million of cash from operations in the quarterManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., No

    11/6/25 4:05:00 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

    DEER PARK, Ill., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Participant Call Link:Click HereWebcast:Click Here   In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@eto

    10/23/25 4:30:00 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results

    Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18th straight quarter of sequential product sales growthQ2 2025 basic and fully diluted GAAP EPS of $(0.10), non-GAAP fully diluted EPS of $0.03, and Adjusted EBITDA of $3.1 millionLaunched KHINDIVI™ (hydrocortisone) Oral SolutionReached 100 active INCRELEX® patients, ahead of previous guidance of year endCompany projects reaching an annual revenue run rate of $80 million in Q3, one quarter ahead of previous guidanceManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative phar

    8/7/25 4:05:00 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Eton Pharmaceuticals Inc.

    SC 13G - Eton Pharmaceuticals, Inc. (0001710340) (Subject)

    12/9/24 4:04:43 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Eton Pharmaceuticals Inc.

    SC 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)

    9/12/24 4:05:13 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Eton Pharmaceuticals Inc. (Amendment)

    SC 13D/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)

    4/30/24 7:00:15 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care